|
1.
|
DK PodolskyInflammatory bowel diseaseN
Engl J Med347417429200210.1056/NEJMra020831
|
|
2.
|
A MizoguchiE MizoguchiInflammatory bowel
disease, past, present and future: lessons from animal modelsJ
Gastroenterol43117200810.1007/s00535-007-2111-318297430
|
|
3.
|
RB SartorMechanisms of disease:
pathogenesis of Crohn’s disease and ulcerative colitisNat Clin
Pract Gastroenterol Hepatol33904072006
|
|
4.
|
A KoboriY YagiH ImaedaInterleukin-33
expression is specifically enhanced in inflamed mucosa of
ulcerative colitisJ
Gastroenterol459991007201010.1007/s00535-010-0245-120405148
|
|
5.
|
L MayerEvolving paradigms in the
pathogenesis of IBDJ
Gastroenterol45916201010.1007/s00535-009-0138-3
|
|
6.
|
WA Faubion JrEV Loftus JrWS HarmsenAR
ZinsmeisterWJ SandbornThe natural history of corticosteroid therapy
for inflammatory bowel disease: a population-based
studyGastroenterology121255260200110.1053/gast.2001.2627911487534
|
|
7.
|
KM TaylorPM IrvingOptimization of
conventional therapy in patients with IBDNat Rev Gastroenterol
Hepatol8646656201110.1038/nrgastro.2011.17221970871
|
|
8.
|
K McSharryAM DalzellK LeiperW
El-MatarySystematic review: the role of tacrolimus in the
management of Crohn’s diseaseAliment Pharmacol
Ther34128212942011
|
|
9.
|
M NaganumaT FujiiM WatanabeThe use of
traditional and newer calcineurin inhibitors in inflammatory bowel
diseaseJ
Gastroenterol46129137201110.1007/s00535-010-0352-z21132334
|
|
10.
|
A BensonT BarrettM SparbergAL
BuchmanEfficacy and safety of tacrolimus in refractory ulcerative
colitis and Crohn’s disease: a single-center experienceInflamm
Bowel Dis147122008
|
|
11.
|
H OgataT MatsuiM NakamuraA randomised dose
finding study of oral tacrolimus (FK506) therapy in refractory
ulcerative
colitisGut5512551262200610.1136/gut.2005.08179416484504
|
|
12.
|
H OgataJ KatoF HiraiDouble-blind,
placebo-controlled trial of oral tacrolimus (FK506) in the
management of hospitalized patients with steroid-refractory
ulcerative colitisInflamm Bowel
Dis18803808201210.1002/ibd.2185321887732
|
|
13.
|
S YamamotoH NakaseM MatsuuraS MasudaK
InuiT ChibaTacrolimus therapy as an alternative to thiopurines for
maintaining remission in patients with refractory ulcerative
colitisJ Clin
Gastroenterol45526530201110.1097/MCG.0b013e318209cdc421336140
|
|
14.
|
S YamamotoH NakaseS MikamiLong-term effect
of tacrolimus therapy in patients with refractory ulcerative
colitisAliment Pharmacol
Ther28589597200810.1111/j.1365-2036.2008.03764.x18549460
|
|
15.
|
RW BusuttilJR LakeRole of tacrolimus in
the evolution of liver
transplantationTransplantation77S44S51200410.1097/01.TP.0000126927.49589.3F15201686
|
|
16.
|
F VincentiA decade of progress in kidney
transplantationTransplantation77S52S61200410.1097/01.TP.0000126928.15055.DC15201687
|
|
17.
|
F RusnakP MertzCalcineurin: form and
functionPhysiological Rev8014831521200011015619
|
|
18.
|
W LiaoJX LinWJ LeonardIL-2 family
cytokines: new insights into the complex roles of IL-2 as a broad
regulator of T helper cell differentiationCurr Opin
Immunol23598604201110.1016/j.coi.2011.08.00321889323
|
|
19.
|
V LazarevicLH GlimcherT-bet in diseaseNat
Immunol12597606201110.1038/ni.205921685955
|
|
20.
|
UP SinghC VenkataramanR SinghJW Lillard
JrCXCR3 axis: role in inflammatory bowel disease and its
therapeutic implicationEndocr Metab Immune Disord Drug
Targets7111123200710.2174/18715300778083210917584151
|
|
21.
|
SJ ConnorN ParaskevopoulosR NewmanCCR2
expressing CD4+ T lymphocytes are preferentially
recruited to the ileum in Crohn’s
diseaseGut5312871294200415306587
|
|
22.
|
O GripS JanciauskieneAtorvastatin reduces
plasma levels of chemokine (CXCL10) in patients with Crohn’s
diseasePLoS One4e5263200919421322
|
|
23.
|
C BanksA BatemanR PayneP JohnsonN
SheronChemokine expression in IBD. Mucosal chemokine expression is
unselectively increased in both ulcerative colitis and Crohn’s
diseaseJ Pathol1992835200312474223
|
|
24.
|
HH ZhangK SongRL RabinCCR2 identifies a
stable population of human effector memory CD4+ T cells
equipped for rapid recall responseJ
Immunol18566466663201010.4049/jimmunol.090415620980630
|
|
25.
|
IF CharoW PetersChemokine receptor 2
(CCR2) in atherosclerosis, infectious diseases, and regulation of
T-cell
polarizationMicrocirculation10259264200310.1080/mic.10.3-4.259.26412851643
|
|
26.
|
YG KimN KamadaMH ShawThe Nod2 sensor
promotes intestinal pathogen eradication via the chemokine
CCL2-dependent recruitment of inflammatory
monocytesImmunity34769780201110.1016/j.immuni.2011.04.01321565531
|
|
27.
|
M LiuS GuoJM HibbertCXCL10/IP-10 in
infectious diseases pathogenesis and potential therapeutic
implicationsCytokine Growth Factor Rev22121130201121802343
|
|
28.
|
S DaneseJF ColombelW ReinischPJ
RutgeertsReview article: infliximab for Crohn’s disease treatment -
shifting therapeutic strategies after 10 years of clinical
experienceAliment Pharmacol Ther338578692011
|
|
29.
|
SB HanauerAA KornbluthJ MessickDT RubinWJ
SandbornBE SandsClinical scenarios in IBD: optimizing the use of
conventional and biologic agentsInflamm Bowel
Dis16S1S11201010.1002/ibd.2152921104734
|
|
30.
|
M AllezS VermeireN MozziconacciThe
efficacy and safety of a third anti-TNF monoclonal antibody in
Crohn’s disease after failure of two other anti-TNF
antibodiesAliment Pharmacol Ther31921012010
|
|
31.
|
YR MahidaJ BeltingerS MakhAdult human
colonic subepithelial myofibroblasts express extracellular matrix
proteins and cyclooxygenase-1 and −2Am J
Physiol273G1341G134819979435560
|
|
32.
|
T OkunoA AndohS BambaInterleukin-1beta and
tumor necrosis factor-alpha induce chemokine and matrix
metalloproteinase gene expression in human colonic subepithelial
myofibroblastsScand J
Gastroenterol37317324200210.1080/003655202317284228
|
|
33.
|
A AndohH TakayaT SaotomeCytokine
regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression
in human pancreatic periacinar
myofibroblastsGastroenterology119211219200010.1053/gast.2000.853810889171
|
|
34.
|
M ShimadaA AndohK HataIL-6 secretion by
human pancreatic periacinar myofibroblasts in response to
inflammatory mediatorsJ
Immunol168861868200210.4049/jimmunol.168.2.86111777983
|
|
35.
|
O InatomiA AndohK KitamuraH YasuiZ ZhangY
FujiyamaButyrate blocks interferon-gamma-inducible protein-10
release in human intestinal subepithelial myofibroblastsJ
Gastroenterol40483489200510.1007/s00535-005-1573-4
|
|
36.
|
XF QiDH KimYS YoonEssential involvement of
cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in
human THP-1 monocytesJ Cell
Physiol220690697200910.1002/jcp.2181519472212
|
|
37.
|
C WuY OhmoriS BandyopadhyayG SenT
HamiltonInterferon-stimulated response element and NF kappa B sites
cooperate to regulate double-stranded RNA-induced transcription of
the IP-10 geneJ Interferon
Res14357363199410.1089/jir.1994.14.3577897255
|
|
38.
|
DB ShultzMR RaniJD FullerRM RansohoffGR
StarkRoles of IKK-beta, IRF1, and p65 in the activation of
chemokine genes by interferon-gammaJ Interferon Cytokine
Res29817824200910.1089/jir.2009.003419929594
|
|
39.
|
CK WongCB WangWK IpYP TianCW LamRole of
p38 MAPK and NF-κB for chemokine release in coculture of human
eosinophils and bronchial epithelial cellsClin Exp
Immunol139901002005
|
|
40.
|
K HataA AndohM ShimadaIL-17 stimulates
inflammatory responses via NF-kappaB and MAP kinase pathways in
human colonic myofibroblastsAm J Physiol Gastrointest Liver
Physiol282G1035G1044200210.1152/ajpgi.00494.200112016129
|
|
41.
|
HC ReineckerEY LohDJ RinglerA MehtaJL
RombeauRP MacDermottMonocyte-chemoattractant protein 1 gene
expression in intestinal epithelial cells and inflammatory bowel
disease
mucosaGastroenterology1084050199510.1016/0016-5085(95)90006-3
|
|
42.
|
M UguccioniP GionchettiDF
RobbianiIncreased expression of IP-10, IL-8, MCP-1, and MCP-3 in
ulcerative colitisAm J
Pathol155331336199910.1016/S0002-9440(10)65128-010433925
|
|
43.
|
P ManousouG KoliosV ValatasIncreased
expression of chemokine receptor CCR3 and its ligands in ulcerative
colitis: the role of colonic epithelial cells in in vitro
studiesClin Exp
Immunol162337347201010.1111/j.1365-2249.2010.04248.x21077277
|
|
44.
|
H HerfarthB Pollok-KoppM GokeA PressM
OppermannPolymorphism of CC chemokine receptors CCR2 and CCR5 in
Crohn’s diseaseImmunol Lett77113117200111377705
|
|
45.
|
H HerfarthM GokeC HellerbrandPolymorphism
of monocyte chemoattractant protein 1 in Crohn’s diseaseInt J
Colorectal Dis184014052003
|
|
46.
|
CE EganMD CravenJ LengM MackKW SimpsonEY
DenkersCCR2-dependent intraepithelial lymphocytes mediate
inflammatory gut pathology during Toxoplasma gondii
infectionMucosal Immunol2527535200910.1038/mi.2009.105
|
|
47.
|
UP SinghS SinghDD TaubJW Lillard
JrInhibition of IFN-gamma-inducible protein-10 abrogates colitis in
IL-10-/-miceJ
Immunol17114011406200310.4049/jimmunol.171.3.140112874231
|
|
48.
|
T YoshinoH NakaseY
HonzawaImmunosuppressive effects of tacrolimus on macrophages
ameliorate experimental colitisInflamm Bowel
Dis1620222033201010.1002/ibd.2131820848491
|
